Lv4
750 积分 2024-06-05 加入
Real-world data of enzyme replacement therapy with pabinafusp alfa for neuronopathic MPS-II: Updated clinical data from Japan
3天前
已完结
An Intravenous Brain-Penetrant Enzyme Therapy for Mucopolysaccharidosis II
4天前
已完结
One Pivotal Trial, the New Default Option for FDA Approval — Ending the Two-Trial Dogma
5天前
已完结
Therapies against chronic hepatitis B infections: The times they are a-changin’, but the changing is slow
7天前
已完结
Dynamic modulation of the blood–brain barrier in the healthy brain
19天前
已完结
Neuro-epithelial circuits promote sensory convergence and intestinal immunity
1个月前
已完结
Agonists for cytosolic bacterial receptor ALPK1 induce antitumour immunity
1个月前
已完结
Bioengineering and nephrology converge to drive kidney-targeted therapies
1个月前
已完结
Innovative antibody therapeutic development in China compared with the USA and Europe
2个月前
已完结
177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial
2个月前
已完结
皖公网安备34019202002308
